We believe personnalized medicine and targeted therapies are amazing therapeutic alternatives for many patients. Our work focus on bringing chemical innovation to antibody-drug conjugates, a sub-class of targeted therapies, in order to ensure optimal characteristics and efficacies. To date, McSAF have developped McSAF Inside® cysteins rebridging technology platforms that can be used to produce three typologies of ADCs:
- DAR 4, i.e. 4 drugs per antibody
- DAR 2, i.e. 2 drugs per antibody
- DAR 1, i.e. 1 drug per antibody
Our technology is offered in partnership with Lonza as part of the Lonza Bioconjugation Toolbox and its Early Development Service (EDS) offering. Lonza can support the entire product lifecycle: from drug discovery and lead identification right through to commercial manufacturing.
McSAF Inside®, a versatile technology
McSAF Inside® results
DAR 4
Results obtained on ADC with MMAE conventional linker (native mass spectrometry analysis)
DAR 2
Results obtained on ADC with MMAE click linker (native mass spectrometry analysis)
DAR 1
Results obtained on ADC with MMAE click linker (mass spectrometry analysis)
PATENTS & PUBLICATIONS
> Novel antibody-drug conjugates and the use of same in therapy Joubert, N ; Viaud-Massuard, MC ; Respaud, R. Patent WO2015004400A1. Patent granted in FR / US / JP / EP / CN / CA
> Antibody-drug conjugates and their use in therapy
Juen, L ; Baltus, CB.
Patent WO2020234541.
> Anti-CD30-drug conjugates and their use in therapy
Juen, L ; Baltus, CB.
Patent WO2021064332.
Patent granted in FR
> Anti-CD56 antibody-drug conjugates and their use in therapy
Juen, L ; Baltus, CB : Desgranges A ; Touzé, A ; Kervarrec, T ; Leblond, V ; Samimi, M.
Patent WO2021170961.
> Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody-Drug Conjugates
Feuillâtre O. et al., ACS Omega, 2020, 5, 1557-1565
>Innovative Bioconjugation Technology for Antibody–Drug Conjugates: Proof of Concept in a CD30-Positive Lymphoma Mouse Model
Juen L. et al., Bioconjugate Chemistry, 2021, 32, 3, 595-606
>Adcitmer®, a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma
Esnault C. et al., British Journal of Dermatology, 2021